O'Brien J F, Meade J L, Falk J L
Department of Emergency Medicine, Orlando Regional Medical Center, Florida.
Ann Emerg Med. 1993 Feb;22(2):212-5. doi: 10.1016/s0196-0644(05)80205-7.
To determine the efficacy of dexamethasone as adjuvant therapy to improve pain relief in patients with severe, acute exudative pharyngitis.
Prospective, randomized, double-blinded, placebo-controlled clinical trial.
Large, urban community hospital emergency department with an emergency medicine residency program.
Patients aged 12 to 65 years old with exudative pharyngitis and severe dysphagia/odynophagia. Patients with cancer, AIDS, diabetes mellitus, recent steroid use, pregnancy, or suspicion of peritonsillar abscess were excluded.
All patients received oral penicillin (500 mg Pen VK) or erythromycin (333 mg base) three times daily for ten days in addition to either 10 mg single-dose dexamethasone or saline placebo IM injection.
Fifty-eight patients graded their initial degree of throat pain on a visual-analog scale that was 15 cm long and scored from 0 to 3.0 in 0.5-cm increments. Follow-up was obtained on 51 patients to determine their condition at 24 hours. At entry, there was no difference in age, weight, antibiotic assignment, or initial pain score between groups. Improvement in pain score (initial versus 24 hours) was 1.8 +/- 0.8 in the 26 patients of the dexamethasone group and 1.2 +/- 0.9 in the 25 patients of the placebo group (P < .05). Time to onset of pain relief was also faster in steroid-treated patients who demonstrated relief beginning at 6.3 +/- 5.3 hours, compared with 12.4 +/- 8.5 hours in the placebo group (P < .01). Of the 26 patients evaluated at seven days (13 in each group), time to complete lack of pain averaged 15.0 +/- 11.4 hours in the dexamethasone group and 35.4 +/- 17.9 hours in the placebo group (P < .02). Complications attributable to dexamethasone were not observed.
In patients with severe, acute exudative pharyngitis, single-injection dexamethasone adjuvant compared with placebo resulted in statistically and clinically significant improvement, as evidenced by more rapid onset and greater degree of pain relief.
确定地塞米松作为辅助治疗手段,对改善重度急性渗出性咽炎患者疼痛缓解情况的疗效。
前瞻性、随机、双盲、安慰剂对照临床试验。
设有急诊医学住院医师培训项目的大型城市社区医院急诊科。
年龄在12至65岁之间,患有渗出性咽炎且伴有严重吞咽困难/吞咽痛的患者。排除患有癌症、艾滋病、糖尿病、近期使用过类固醇、怀孕或疑似扁桃体周围脓肿的患者。
所有患者除接受单剂量10毫克地塞米松或生理盐水安慰剂肌肉注射外,均每日口服青霉素(500毫克青霉素V钾)或红霉素(333毫克碱)三次,持续十天。
58名患者使用15厘米长的视觉模拟量表对其初始咽痛程度进行评分,量表从0至3.0,以0.5厘米为增量。对51名患者进行随访,以确定他们24小时后的状况。入组时,两组患者在年龄、体重、抗生素分配或初始疼痛评分方面无差异。地塞米松组的26名患者疼痛评分改善情况(初始评分与24小时后评分)为1.8±0.8,安慰剂组的25名患者为1.2±0.9(P<.05)。类固醇治疗组患者疼痛缓解开始时间也更快,为6.3±5.3小时,而安慰剂组为12.4±8.5小时(P<.01)。在七天时评估的26名患者(每组13名)中,地塞米松组完全无痛的平均时间为15.0±11.4小时,安慰剂组为35.4±17.9小时(P<.02)。未观察到与地塞米松相关的并发症。
在重度急性渗出性咽炎患者中,与安慰剂相比,单次注射地塞米松辅助治疗在统计学和临床上均有显著改善,表现为疼痛缓解起效更快、程度更大。